Burzynski Research Institute Inc.
OTC
Real-time Data
01:30 PM
Day's Range
0.0050052 wk Range
0.00400Key Statistics
Symbol
BZYR
Name
Burzynski Research Institute Inc.
Currency
USD
Exchange
OTC
High
0.0060000001
Low
0.0049999999
Open
‪0.00500‬
Last
‪0.00600‬
Market Cap
525.79K
Pe Ratio
‪-0.60‬
Volume
12.00K
Average Volume
3.66K
Dividend Yield
‪0.00%‬
Change
0.0020
Percent Change
50.00
Timestamp
2026-07-17
Close
0.0060000001
Today Range Start
‪0.00500‬
Today Range End
‪0.00600‬
52 Week Range Start
‪0.00400‬
52 Week Range End
‪0.0500‬
Type
Stocks
Country
United States
Compliance - BZYR - Burzynski Research Institute Inc.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-16
Business Screen
NON_COMPLIANT
Financial Screen
COMPLIANT
Compliant Revenue
‪80.00%‬
Non Compliant Revenue
‪12.00%‬
Questionable Revenue
‪8.00%‬
Securities To Market Cap Ratio
‪1.00%‬
Debt To Market Cap Ratio
‪3.00%‬
Historical Data - BZYR - Burzynski Research Institute Inc.
Historical Data
Market Cap - BZYR - Burzynski Research Institute Inc.
Market Cap
2026-07-16
525.79K
2026-07-15
525.79K
2026-07-13
657.24K
2026-07-10
657.24K
2026-07-09
525.79K
2026-07-07
657.24K
2026-07-06
657.24K
2026-07-01
920.13K
2026-06-30
788.69K
2026-06-29
657.24K
Earnings - BZYR - Burzynski Research Institute Inc.
Earnings
Balance Sheet - BZYR - Burzynski Research Institute Inc.
Balance Sheet
| Period Ending | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 |
|---|---|---|---|---|---|---|
 Assets | 847 | 2.31K | 1.93K | 4.66K | 956 | 19.85K |
| Liabilities | 42.48K | 27.43K | 15.66K | 3.45K | 46.79K | 172.44K |
| Shareholders Equity | -41.63K | -25.12K | -13.72K | 1.20K | -45.84K | -152.58K |
Cash Flow - BZYR - Burzynski Research Institute Inc.
Cash Flow
| Period Ending | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 |
|---|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - | - |
| Investing Activities | - | - | - | - | - | - |
| Financing Activities | - | - | - | - | - | - |
| End Cash Position | 847 | 1.31K | 934 | 3.38K | 62 | 163 |
| Income Tax Paid | - | - | - | - | - | - |
| Interest Paid | - | - | - | - | - | - |
| Free Cash Flow | -388.53K | -523.78K | -249.51K | -325.09K | -394.36K | -530.11K |
Income Statement - BZYR - Burzynski Research Institute Inc.
Income Statement
| Period Ending | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 | 2020-02-29 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expense | - | - | - | - | - | - |
| Operating Income | -1.38M | -1.33M | -916.29K | -976.65K | -1.30M | -1.63M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | 97.77K | 500 |
| Pre Tax Income | -1.38M | -1.33M | -916.29K | -976.65K | -1.20M | -1.63M |
| Income Tax | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -1.38M | -1.33M | -916.29K | -976.65K | -1.20M | -1.63M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Basic Shares Outstanding | 131.44M | 131.44M | 131.44M | 131.44M | 131.44M | 131.44M |
| Diluted Shares Outstanding | 131.44M | 131.44M | 131.44M | 131.44M | 131.44M | 131.44M |
| Ebit | -1.38M | -1.33M | -916.29K | -976.65K | -1.30M | -1.63M |
| Ebitda | -1.38M | -1.33M | -916.29K | -976.65K | -1.30M | -1.63M |
| Net Income Continuous Operations | -1.38M | -1.33M | -916.29K | -976.65K | -1.20M | -1.63M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
Profile - BZYR - Burzynski Research Institute Inc.
Profile
Mic Code
PINX
Sector
Healthcare
Industry
Biotechnology
Employees
0
Burzynski Research Institute Inc. is a biomedical company focused on the research and development of innovative cancer therapies. The company's primary mission is to advance the effectiveness of cancer treatment through pioneering research in antineoplaston therapies, which are designed to target and correct the abnormalities in cancer cells. Burzynski Research Institute operates within the highly specialized biotechnology sector, which plays a crucial role in advancing medical sciences and improving patient outcomes. By participating in clinical trials and engaging in rigorous scientific study, the company contributes to the broader healthcare field's understanding of cancer treatment. With its headquarters in Texas, the institute collaborates with health professionals, research scientists, and other stakeholders to push the boundaries of traditional cancer therapies. The research and outcomes of Burzynski Research Institute are significant to the market as they hold the potential to create cutting-edge treatments that could benefit patients worldwide, influencing the future landscape of cancer management and therapy development.
Profile Details
Type
Common Stock
Ceo
Dr. Stanislaw R. Burzynski M.D., Ph.D.
Address
9432 Katy Freeway
City
Houston
State
TX
Zip
77055
Country
United States
Phone
713 335 5697
